Chee W. Ong

Belfast, NIR, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.

Correction to: NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.

Journal: Prostate cancer and prostatic diseases

Published: March 15, 2022

NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.

NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.

Journal: Prostate cancer and prostatic diseases

Published: November 05, 2021

Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.

Attenuating Adaptive VEGF-A and IL8 Signaling Restores Durable Tumor Control in AR Antagonist-Treated Prostate Cancers.

Journal: Molecular cancer research : MCR

Published: September 13, 2021

Clinical implications of systemic and local immune responses in human angiosarcoma.

Clinical implications of systemic and local immune responses in human angiosarcoma.

Journal: NPJ precision oncology

Published: August 12, 2020

Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma.

Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma.

Journal: NAR cancer

Published: April 22, 2020

Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists.

Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists.

Journal: Cell death & disease

Published: June 14, 2018

Genetics of lipid metabolism in prostate cancer.

Genetics of lipid metabolism in prostate cancer.

Journal: Nature genetics

Published: January 17, 2018

A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases.

A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases.

Journal: The journal of pathology. Clinical research

Published: July 04, 2017

Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.

Erratum to: JMJD6 is a driver of cellular proliferation and motility and a marker of poor prognosis in breast cancer.

Journal: Breast cancer research : BCR

Published: March 06, 2017

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

Journal: Oncotarget

Published: July 22, 2015

PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry.

PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry.

Journal: Human pathology

Published: July 09, 2015

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 11, 2015

Showing 1-12 of 20

Last Updated: 09/26/2026